PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

(zileuton extended-release)

ZYFLO (zileuton)

Status: CVS Caremark® Criteria Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Zileuton extended-release

Zileuton Extended-Release tablets is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton Extended-Release tablets are not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with Zileuton Extended-Release tablets can be continued during acute exacerbations of asthma.

Zyflo

Zyflo is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the prophylaxis or chronic treatment of asthma AND
 - The patient is 12 years of age or older

Duration of Approval (DOA):

• 5090-A: DOA: 12 months

REFERENCES

- Zileuton Extended-Release [package insert]. East Brunswick, NJ: Rising Pharmaceuticals, Inc.; March 2023.
- 2. Zyflo [package insert]. Cary, NC: Chiesi USA, Inc.; January 2017.
- 3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. https://online.lexi.com. Accessed August 8, 2023.
- 4. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 07/13/2023).

Zileuton PA Policy 5090-A UDR 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.